Skip to navigation Skip to content

Cardiomyopathy (CM) Program in Pharmaceutical Benefits Scheme (PBS) 012-24041204

Expand/Collapse all sectionsExpand all


CM restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS CM restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial authority application form (PB360)

Transthyretin amyloid cardiomyopathy - tafamidis - initial authority application form (PB358)

Services Australia website

Cardiomyopathy

External websites

PBS schedule for:

FAQs from Service Officers

Table 1: for FAQs about all Complex programs, see Table 2 in Processing Complex Authority Required Listings.

Item

Description

1

If a change of dose in mavacamten is required after an initial is approved but before 12 weeks, can the change of dose be approved under the first continuing treatment?

Yes.

2

Can a patient have multiple first continuing approvals of different strengths of mavacamten until they can achieve a stable dose?

Yes. The patient’s authorities remain being approved as the first continuing until they are stable on the same dose for a period of 6 months. As such, they can have multiple first continuing approvals of different strengths until a stable dose is achieved.